Ocular inflammation and pain are a common consequence of cataract surgery, and if left untreated, may lead to extensive ocular damage, resulting in impaired vision as well as decreased satisfaction with the procedure. Effective management of ophthalmic inflammation after surgery is therefore vital. Topical ophthalmic non-steroidal anti-inflammatory drugs (NSAIDs) have become a mainstay of management of ocular pain and inflammation as a result of their anti-inflammatory activity, analgesic property and established safety record. Numerous studies have demonstrated the efficacy of topical NSAIDs in post-operative prevention of ocular inflammation, inhibition of intra-operative miosis, reduction of pain associated with cataract surgery and pre-operative use to prevent cystoid macular oedema. Studies have also indicated that NSAIDs and steroids act synergistically when administered together, and that a combination of steroid and NSAID therapy is recommended to achieve successful outcomes. With appropriate administration, NSAIDs are safe and effective therapeutic agents, which rarely result in serious local and systemic responses.
1
Two agents are primarily employed for the reduction of intraocular inflammation: non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids. NSAIDs are potent inhibitors of cyclo-oxygenase enzymes and hence of PG synthesis. Together with corticosteroids, they act on the COX-1 and COX-2 pathways. While corticosteroids inhibit phospholipase A 2 , preventing arachidonic acid release from phospholipids, NSAIDs act downstream and more specifically in the cascade by direct inhibition of COX-1 and COX-2 enzymes (see Figure 1) . 2 Post-operative ocular inflammation is a complex condition owing to the diverse types of tissues that may be affected, including the conjunctiva, retina, sclera, aqueous and vitreous humour, cornea, iris, ciliary body, choroid and retina. recently developed is nepafenac 0.10 %, an amide prodrug that is converted to its active form, amfenac, by intraocular hydrolases. 6 A multicentre double-masked study (n=75) aiming to evaluate the aqueous humour concentrations and COX inhibitory activities of nepafenac, amfenac, ketorolac and bromfenac after topical ocular administration demonstrated that, for example, nepafenac has significantly greater ocular bioavailability than ketorolac tromethamine (see Figure 2 ). 7 Being less polar than other NSAIDs, nepafenac is able to easily penetrate the cornea, enhancing corneal epithelial absorption. 8 As a result, nepafenac is optimally distributed in the cornea, iris, ciliary body and retina/choroid and has longer duration of action at these sites. In terms of safety, the prodrug structure minimises surface accumulation, as it is rapidly distributed through the cornea to the anterior and posterior chambers. As a result, ocular surface complications associated with conventional NSAID therapies may be reduced.
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Efficacy Studies Involving Topical Non-steroidal Anti-inflammatory Drugs
Considerable evidence exists to support the use of topical NSAIDs in place of or in addition to topical corticosteroids after cataract surgery, to avoid excessive inflammation and aid in visual recovery. 
Effect of Non-steroidal Anti-inflammatory Drugs on Intra-operative Miosis
The maintenance of mydriasis is critical during cataract surgery to allow adequate access to the extraction of the crystalline lens and implantation of the IOL without causing trauma to the iris. However, surgically induced miosis is a common complication of cataract surgery as a result of the release of PGs. Miosis may obstruct the surgeon's view during cataract surgery, complicating the procedure and increasing the risk of post-operative inflammation, vitreous loss and capsule rupture. 15, 16 NSAIDs inhibit PG synthesis, subsequently inhibiting intra-operative miosis, as several studies have demonstrated. Topical ketorolac was found to inhibit miosis more effectively than topical diclofenac during extracapsular cataract extraction and intraocular implantation, and gave a more stable mydriatic effect during surgery. 17 NSAIDs also increase the cost-effectiveness of the procedure; the use of ketorolac eliminated the need for the combination of a pre-operative NSAID (flurbiprofen) and post-operative corticosteroid for the prevention of intra-operative miosis and post-operative inflammation in cataract surgery. 18 A study comparing the effects of topical ketorolac 0.5 % with topical 0.03 % flurbiprofen on the inhibition of surgically induced miosis during phacoemulsification cataract surgery concluded that topical ketorolac is an effective inhibitor of miosis during phacoemulsification cataract surgery and confers a stable mydriatic effect throughout surgery. 15 In a prospective, randomised, single-masked comparative study (n=60) of nepafenac, the difference in mean pupil size following phacoemulsification cataract surgery between the control group (6.84±0.93 mm) and the nepafenac group (7.91±0.74 mm) was statistically significant (p<0.001). angiography. A study found that patients who had angiographic CMO at day 60 were more likely to have had more post-operative inflammation than patients who did not develop CMO. 21 The exact incidence of overt CMO varies widely but studies suggest that the rate of clinical CMO following modern cataract surgical techniques ranges from 1 to 2 %. 22 The incidence of angiographic CMO may be as high as 19 %. 21 CMO frequently has a late onset, occurring Source: Lane, et al., 2007. 6 cases of cataract surgery performed by residents over a five-year period. When patients with diabetes were excluded, the rate of CMO was 2.1 %. 24 In a prospective study to compare the efficacy of several prophylactic regimens with ketorolac tromethamine 0.4 %, pre-treatment with NSAID improved visual acuity outcomes significantly in the immediate post-operative period (at one day and two weeks) compared with pre-treatment for one hour or placebo (p<0.05 for all). 25 Bromfenac has also been found to have efficacy in preventing CMO after cataract surgery in patients with diabetes. 26 More recently, a randomised study was conducted for comparing 
Non-steroidal Anti-inflammatory Drugs and Pain Relief
NSAIDs provide effective reduction of pain associated with cataract procedures. In a single-centre, double-masked, randomised, placebo-controlled study of 25 patients undergoing cataract surgery, patients reported significantly less ocular pain during the 24 hours following surgery when treated with ketorolac 0.4 % than with placebo (p=0.02). Ocular pain was reported for only a single ketorolac 0.4 %-treated eye (4 %) during that period, compared with 39 % of placebo-treated eyes (p=0.004). 28 In a larger study (n=100), patients treated with ketorolac tromethamine experienced less intra-operative and post-operative pain compared with a placebo group and did not require additional anaesthesia. 25 In a large trial of bromfenac (n=872), the proportion of patients that were pain-free at one, three and 15 days were significantly higher in the treatment group than in the placebo group. 14 In a multicentre, randomised, placebo-and active-controlled, double-masked clinical trial (n=227), more patients were pain-free at each time-point from day three post-operatively with nepafenac than with placebo, (p<0.05) (see Figure 5 ). 29 Pain reduction is an important consideration because patient expectations of outcomes are high in modern cataract surgery and ocular pain or discomfort is a common cause of patient dissatisfaction.
Safety Issues Associated with the Use of Non-steroidal Anti-inflammatory Drugs
Many topical NSAIDs in ophthalmic use can cause a range of adverse events including conjunctival hyperaemia, burning, stinging and corneal anaesthesia. 30, 31 A more serious complication is the risk of indolent corneal ulceration and full-thickness corneal melts.
Scleral wound melting may arise with any ophthalmic NSAID in patients who have undergone cataract surgery. Moreover, a study found that cases of corneal melt following use of NSAIDs found inconsistent and variable dose/toxicity relationships suggesting that factors other than simple drug toxicity are involved. Corneal melts were found to be more commonly associated with the use of generic NSAIDs. 32 The use of nepafenac in accordance with its approved indications and posology has not been associated with high levels of ocular irritation. Nardi, et al., 2007. 29 
